vs

Side-by-side financial comparison of APOGEE ENTERPRISES, INC. (APOG) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

APOGEE ENTERPRISES, INC. is the larger business by last-quarter revenue ($351.4M vs $207.3M, roughly 1.7× Ultragenyx Pharmaceutical Inc.). APOGEE ENTERPRISES, INC. runs the higher net margin — 4.7% vs -62.0%, a 66.8% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 1.6%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 2.9%).

Apogee Electronics is an American manufacturer of audio interfaces, analog-to-digital and digital-to-analog converters, USB & iOS microphones, and audio production software.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

APOG vs RARE — Head-to-Head

Bigger by revenue
APOG
APOG
1.7× larger
APOG
$351.4M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+24.3% gap
RARE
25.9%
1.6%
APOG
Higher net margin
APOG
APOG
66.8% more per $
APOG
4.7%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
2.9%
APOG

Income Statement — Q4 FY2026 vs Q4 FY2025

Metric
APOG
APOG
RARE
RARE
Revenue
$351.4M
$207.3M
Net Profit
$16.6M
$-128.6M
Gross Margin
22.4%
Operating Margin
7.3%
-54.7%
Net Margin
4.7%
-62.0%
Revenue YoY
1.6%
25.9%
Net Profit YoY
568.8%
3.5%
EPS (diluted)
$0.78
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APOG
APOG
RARE
RARE
Q1 26
$351.4M
Q4 25
$348.6M
$207.3M
Q3 25
$358.2M
$159.9M
Q2 25
$346.6M
$166.5M
Q1 25
$345.7M
$139.3M
Q4 24
$341.3M
$164.6M
Q3 24
$342.4M
$139.5M
Q2 24
$331.5M
$147.0M
Net Profit
APOG
APOG
RARE
RARE
Q1 26
$16.6M
Q4 25
$16.5M
$-128.6M
Q3 25
$23.6M
$-180.4M
Q2 25
$-2.7M
$-115.0M
Q1 25
$2.5M
$-151.1M
Q4 24
$21.0M
$-133.2M
Q3 24
$30.6M
$-133.5M
Q2 24
$31.0M
$-131.6M
Gross Margin
APOG
APOG
RARE
RARE
Q1 26
22.4%
Q4 25
23.8%
Q3 25
23.1%
Q2 25
21.7%
Q1 25
21.6%
Q4 24
26.1%
Q3 24
28.4%
Q2 24
29.8%
Operating Margin
APOG
APOG
RARE
RARE
Q1 26
7.3%
Q4 25
7.1%
-54.7%
Q3 25
7.5%
-106.9%
Q2 25
2.0%
-64.8%
Q1 25
1.8%
-102.6%
Q4 24
8.4%
-74.3%
Q3 24
12.3%
-94.6%
Q2 24
12.5%
-79.1%
Net Margin
APOG
APOG
RARE
RARE
Q1 26
4.7%
Q4 25
4.7%
-62.0%
Q3 25
6.6%
-112.8%
Q2 25
-0.8%
-69.0%
Q1 25
0.7%
-108.5%
Q4 24
6.1%
-80.9%
Q3 24
8.9%
-95.7%
Q2 24
9.4%
-89.5%
EPS (diluted)
APOG
APOG
RARE
RARE
Q1 26
$0.78
Q4 25
$0.77
$-1.28
Q3 25
$1.10
$-1.81
Q2 25
$-0.13
$-1.17
Q1 25
$0.12
$-1.57
Q4 24
$0.96
$-1.34
Q3 24
$1.40
$-1.40
Q2 24
$1.41
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APOG
APOG
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$39.5M
$421.0M
Total DebtLower is stronger
$232.3M
Stockholders' EquityBook value
$511.8M
$-80.0M
Total Assets
$1.1B
$1.5B
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APOG
APOG
RARE
RARE
Q1 26
$39.5M
Q4 25
$41.3M
$421.0M
Q3 25
$39.5M
$202.5M
Q2 25
$32.8M
$176.3M
Q1 25
$41.4M
$127.1M
Q4 24
$43.9M
$174.0M
Q3 24
$51.0M
$150.6M
Q2 24
$30.4M
$480.7M
Total Debt
APOG
APOG
RARE
RARE
Q1 26
$232.3M
Q4 25
Q3 25
Q2 25
Q1 25
$285.0M
Q4 24
Q3 24
Q2 24
Stockholders' Equity
APOG
APOG
RARE
RARE
Q1 26
$511.8M
Q4 25
$512.3M
$-80.0M
Q3 25
$500.2M
$9.2M
Q2 25
$481.8M
$151.3M
Q1 25
$487.9M
$144.2M
Q4 24
$522.1M
$255.0M
Q3 24
$506.4M
$346.8M
Q2 24
$480.0M
$432.4M
Total Assets
APOG
APOG
RARE
RARE
Q1 26
$1.1B
Q4 25
$1.1B
$1.5B
Q3 25
$1.2B
$1.2B
Q2 25
$1.2B
$1.3B
Q1 25
$1.2B
$1.3B
Q4 24
$1.2B
$1.5B
Q3 24
$917.1M
$1.5B
Q2 24
$889.0M
$1.6B
Debt / Equity
APOG
APOG
RARE
RARE
Q1 26
0.45×
Q4 25
Q3 25
Q2 25
Q1 25
0.58×
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APOG
APOG
RARE
RARE
Operating Cash FlowLast quarter
$122.5M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
7.8%
0.5%
Cash ConversionOCF / Net Profit
7.37×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APOG
APOG
RARE
RARE
Q1 26
$122.5M
Q4 25
$29.3M
$-99.8M
Q3 25
$57.1M
$-91.4M
Q2 25
$-19.8M
$-108.3M
Q1 25
$30.0M
$-166.5M
Q4 24
$31.0M
$-79.3M
Q3 24
$58.7M
$-67.0M
Q2 24
$5.5M
$-77.0M
Free Cash Flow
APOG
APOG
RARE
RARE
Q1 26
Q4 25
$22.9M
$-100.8M
Q3 25
$52.4M
$-92.7M
Q2 25
$-26.9M
$-110.7M
Q1 25
$19.1M
$-167.8M
Q4 24
$22.0M
$-79.5M
Q3 24
$50.2M
$-68.6M
Q2 24
$-1.8M
$-79.0M
FCF Margin
APOG
APOG
RARE
RARE
Q1 26
Q4 25
6.6%
-48.6%
Q3 25
14.6%
-58.0%
Q2 25
-7.8%
-66.5%
Q1 25
5.5%
-120.5%
Q4 24
6.4%
-48.3%
Q3 24
14.7%
-49.2%
Q2 24
-0.5%
-53.7%
Capex Intensity
APOG
APOG
RARE
RARE
Q1 26
7.8%
Q4 25
1.9%
0.5%
Q3 25
1.3%
0.8%
Q2 25
2.1%
1.5%
Q1 25
3.2%
1.0%
Q4 24
2.6%
0.1%
Q3 24
2.5%
1.2%
Q2 24
2.2%
1.4%
Cash Conversion
APOG
APOG
RARE
RARE
Q1 26
7.37×
Q4 25
1.77×
Q3 25
2.41×
Q2 25
Q1 25
12.08×
Q4 24
1.48×
Q3 24
1.92×
Q2 24
0.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

APOG
APOG

Architectural Services$127.1M36%
Architectural Metals$110.0M31%
Architectural Glass$67.4M19%
Performance Surfaces$54.3M15%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons